{
    "clinical_study": {
        "@rank": "121118", 
        "arm_group": {
            "arm_group_label": "M22 IPL and ResurFX", 
            "arm_group_type": "Experimental", 
            "description": "The procedure will include an intense pulse light (IPL) treatment followed by fractional non-ablative (FNA) treatment."
        }, 
        "brief_summary": {
            "textblock": "Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of\n      3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their\n      facial skin appearance.\n\n      Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or\n      pigmentation by at least 1 on the FES scale or \u226550% in category scale at 3 months follow-ups\n      in at least 50% of the study population."
        }, 
        "brief_title": "Impact of M22 Synergistic Sequential Treatment (SST)", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Improvement of Wrinkles/Elastosis and/or Pigmentation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Able to read, understand and provide written Informed Consent;\n\n          2. Healthy adult, male or  female, 30-65 years of age with Fitzpatrick-Goldman skin type\n             I-V;\n\n          3. Having suitable facial areas with wrinkles Fitzpatrick-Goldman Wrinkle and Elastosis\n             Score of 3-6 to be treated;\n\n          4. Having suitable facial areas with mild to moderate age/sun-related facial\n             pigmentation\n\n          5. Able and willing to comply with the treatment/follow-up schedule and requirements;\n\n          6. Women of child-bearing age are required to be using a reliable method of birth\n             control (such as an intrauterine device, birth control pills, condom with\n             spermicidal, Nova ring, partner with vasectomy or abstinence) at least 3 months prior\n             to enrollment and throughout the course of the study.\n\n        Exclusion Criteria:\n\n          1. Skin type VI\n\n          2. Pregnant, intending to become pregnant during the course of study, less than 3 months\n             postpartum or less than 6 weeks after completion of breastfeeding\n\n          3. Heavy smoker (>1 pack of cigarettes a day)\n\n          4. Unable or unlikely to refrain from tanning, including the use of tanning booths,\n             during the course of the study\n\n          5. Use of photosensitive medication for which light exposure is contraindicated.\n\n          6. Use of oral isotretinoin (Accutane\u00ae) within 3 months of initial treatment or during\n             the course of the study. Note: skin must regain its normal degree of moisture prior\n             to treatment.\n\n          7. Having indurate acne in treated area.\n\n          8. Any dermal/epidermal damage or disorder, mainly vascular or textural lesions, in\n             treated area\n\n          9. Prior treatment, such as chemical peel (especially phenol based) or dermabrasion, in\n             treated area within 3 months of initial treatment or during the course of the study;\n\n         10. Prior skin laser/light or another device treatment in treated area within 6 months of\n             initial treatment or during the course of the study\n\n         11. Prior use of collagen, fat injections or other methods of skin augmentation\n             (enhancement with injected or implanted material) in treated area within 12 months of\n             initial treatment or during the course of the study. Treatment may not be performed\n             at all over permanent dermal implants\n\n         12. Prior use of Botox in treatment area within 6 months\n\n         13. Prior ablative resurfacing procedure or face lift in treated area with laser or other\n             devices within 12 months of initial treatment or during the course of the study\n\n         14. Any other surgery in treated area within 9 months of initial treatment or during the\n             course of the study.\n\n         15. Participation in a study of another investigational device or drug involving the same\n             anatomical site within 3 months prior to enrollment or during this evaluation, or if\n             not involving the same anatomical site, as per the Investigator's discretion\n\n         16. History of keloid or any other type of hypertrophic scar formation or poor wound\n             healing in a previously injured skin area\n\n         17. Showing symptoms of hormonal disorders, as per the Investigator's discretion (such as\n             Melasma, Chloasma)\n\n         18. Concurrent inflammatory skin conditions, Open laceration or abrasion of any sort on\n             area to be treated during the course of treatment\n\n         19. Active Herpes Simplex at the time of treatment or having experienced more than three\n             episodes of Herpes Simplex eruption within a year of study enrollment;\n\n         20. Multiple dysplastic nevi in area to be treated\n\n         21. Having a bleeding disorder or taking anticoagulation medications, including heavy use\n             of aspirin, in a manner which does not allow for a minimum 10 day washout period\n             prior to treatment (as per the subject's physician discretion)\n\n         22. History of immunosuppression/immune deficiency disorders (including HIV infection or\n             AIDS) or use of immunosuppressive medications\n\n         23. Having any form of active cancer at the time of enrollment and during the course of\n             the study or history of skin cancer on the face.\n\n         24. Pigmented lesion in the treated area that appears cancerous or is not deemed suitable\n             for photo therapy, as determined by a dermatologist.\n\n         25. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state\n             that in the opinion of the Investigator would interfere with the anesthesia,\n             treatment, or healing process;\n\n         26. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse\n\n         27. Any condition which, in the Investigator's opinion, would make it unsafe (for the\n             subject or for the study personnel) to treat the subject as part of this research\n             study.\n\n         28. For subjects undergoing test spots: considerable undesired response consisting of\n             skin hypopigmentation (long term whitening), a scar or pre scar formation, or any\n             response deemed by the Investigator as grounds for exclusion.\n\n         29. Allergies to anesthetics."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032771", 
            "org_study_id": "LUM-ABU-M22-IPL&ResurFX-13-02"
        }, 
        "intervention": {
            "arm_group_label": "M22 IPL and ResurFX", 
            "description": "The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.", 
            "intervention_name": "M22 IPL and ResurFX", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "contact": {
                "last_name": "Marissa J. Knight"
            }, 
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32801"
                }, 
                "name": "Knight Dermatology Institute"
            }, 
            "investigator": {
                "last_name": "Matthew J. Knight, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Impact of M22 Synergistic Sequential Treatment (SST) Using Intense Pulsed Light and Fractional Non-ablative Photothermolysis on Skin Texture", 
        "overall_contact": {
            "email": "mjkderm@gmail.com", 
            "last_name": "Marissa J. Knight", 
            "phone": "407.992.0660"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Skin improvement by Fitzpatrick Elastosis Scale (FES) or category scale at 3 months based on before/after photos", 
            "measure": "Percentage of Participants with \u2265 50% improvement in Fitzpatrick Elastosis Scale (FES)", 
            "safety_issue": "No", 
            "time_frame": "3 months following 3rd treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032771"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall skin improvement at 1 and 6 months by subject and investigator evaluation compared to baseline using the category global aesthetic improvement (GAI) scale", 
                "measure": "Percentage of Participants with \u2265 50% improvement in Fitzpatrick Elastosis Scale (FES)", 
                "safety_issue": "No", 
                "time_frame": "1 and 6 months following 3rd treatment"
            }, 
            {
                "description": "Immediate response (erythema, edema, purpura, etc.) of the skin will be assessed within 20-30 min post treatment by a 5 level scale: (0) None / (1) Trace / (2) Mild / (3) Moderate / (4) Severe.", 
                "measure": "Change in erythema/ edema/ purpura and the response intensity", 
                "safety_issue": "Yes", 
                "time_frame": "Following treatments- Baseline, 4, 8 weeks"
            }, 
            {
                "description": "Downtime defined as the period of time following the procedure during which the subject felt unable/unwilling to go out in public due to edema and / or erythema.", 
                "measure": "Downtime in days", 
                "safety_issue": "Yes", 
                "time_frame": "Following treatment- baseline, 4, 8 weeks"
            }, 
            {
                "description": "Subject assessment of pain and discomfort associated with treatments using a  Pain Visual Analogue Scale (VAS), were 0 is \"no pain\" and 100 is \"intolerable pain\".", 
                "measure": "Subject Comfort using a  Pain Visual Analogue Scale (VAS)", 
                "safety_issue": "Yes", 
                "time_frame": "Following treatment- baseline, 4, 8 weeks"
            }, 
            {
                "description": "Subject subjective opinion of improvement and satisfaction with the treatment using the global aesthetic improvement (GAI) scale and pigment Improvement score.", 
                "measure": "Subject subjective assessment of improvement using categorical improvement scales", 
                "safety_issue": "No", 
                "time_frame": "Following treatments-  4, 8 weeks and 1, 3 and 6 months follow up"
            }, 
            {
                "description": "Skin safety throughout the study as determined by the investigator by examining the post-treatment occurrences of complications and adverse events.", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Following treatment #1, 2 and 3 and all follow up visits"
            }
        ], 
        "source": "Lumenis Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lumenis Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}